Data Provided by Refinitiv. Minimum 15 minutes delayed.
Developing novel therapeutics for the treatment of rare diseases.
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome